Cara Therapeutics (CARA) Now Covered by Seaport Global Securities

Stock analysts at Seaport Global Securities began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a note issued to investors on Friday, Marketbeat Ratings reports. The firm set a “buy” rating and a $27.00 price target on the biopharmaceutical company’s stock. Seaport Global Securities’ price objective indicates a potential upside of 107.69% from the company’s previous close.

Other analysts also recently issued reports about the company. Stifel Nicolaus reiterated a “buy” rating and set a $17.00 target price on shares of Cara Therapeutics in a research note on Wednesday, January 3rd. Zacks Investment Research downgraded Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. BMO Capital Markets restated a “market perform” rating and issued a $25.00 price target on shares of Cara Therapeutics in a research note on Tuesday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Cara Therapeutics in a research note on Wednesday, October 4th. Finally, ValuEngine downgraded Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Cara Therapeutics currently has an average rating of “Buy” and a consensus target price of $25.09.

Shares of Cara Therapeutics (CARA) traded up $0.56 on Friday, reaching $13.00. The company’s stock had a trading volume of 1,105,022 shares, compared to its average volume of 931,163. Cara Therapeutics has a 1-year low of $11.11 and a 1-year high of $28.50. The stock has a market cap of $442.99, a P/E ratio of -5.68 and a beta of 2.96.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same quarter last year, the firm posted ($0.42) earnings per share. research analysts forecast that Cara Therapeutics will post -1.84 earnings per share for the current year.

In related news, CEO Derek T. Chalmers sold 16,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $12.66, for a total value of $202,560.00. Following the transaction, the chief executive officer now directly owns 1,066,292 shares of the company’s stock, valued at approximately $13,499,256.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in CARA. Rhumbline Advisers raised its holdings in Cara Therapeutics by 16.7% in the 2nd quarter. Rhumbline Advisers now owns 30,537 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 4,375 shares during the period. Bank of New York Mellon Corp raised its holdings in Cara Therapeutics by 26.1% during the second quarter. Bank of New York Mellon Corp now owns 177,766 shares of the biopharmaceutical company’s stock valued at $2,735,000 after acquiring an additional 36,769 shares during the period. Legal & General Group Plc raised its holdings in Cara Therapeutics by 10.4% during the second quarter. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 678 shares during the period. Swiss National Bank bought a new stake in Cara Therapeutics during the second quarter valued at about $651,000. Finally, Alliancebernstein L.P. raised its holdings in Cara Therapeutics by 90.1% during the second quarter. Alliancebernstein L.P. now owns 38,600 shares of the biopharmaceutical company’s stock valued at $594,000 after acquiring an additional 18,300 shares during the period. 58.64% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Cara Therapeutics (CARA) Now Covered by Seaport Global Securities” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/20/cara-therapeutics-cara-now-covered-by-seaport-global-securities.html.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply